Fujifilm Restarting Avigan Trial in Japan to Treat COVID-19

Fujifilm suffered a setback with Avigan in December after the trial data was considered to be inconclusive since it wasn’t a double-blind study. Fujifilm’s new study will involve about 270 patients with the goal of seeking approval again in October for the treatment of mildly sick patients that are not pregnant.

Fujifilm is expected to test Avigan on patients with mild symptoms that are 65 or older along with mildly ill patients 50 or older with preexisting conditions like kidney disease and diabetes. Currently, Avigan is approved for the treatment of COVID-19 in  India and Indonesia.

Other Avigan/COVID-19/Hydro Ag +/Fujifilm Biomedical Coverage (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

Please don’t forget to follow us on FacebookTwitterInstagramYouTube

Plus our owners’ groups
Fujifilm GFX Owners Group
Fujifilm X-H Owners Group
Fujifilm X-T Owners Group
Fujifilm X-S Owners Group
Fujifilm X-Pro Owners Group
Fujifilm X-E Owners Group
Fujifilm X-A Owners Group
Fujifilm X100 Owners Group

via nikkei

This entry was posted in Press releases and tagged , , , , , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.
  • FCC disclosure statement: this post may contain affiliate links or promotions that do not cost readers anything but help keep this website alive. Thanks for your support!